Clínica Médica

[Preprint] Estudo de coorte retrospectiva | 2º reforço de vacina e mortalidade por Covid-19 em adultos de 60 a 100 anos de idade.

31 Mar, 2022 | 13:44h

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Comentários:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

---

EUA aprovam 2ª dose de reforço contra Covid-19 para pessoas de 50 anos de idade ou mais e indivíduos imunocomprometidos.

31 Mar, 2022 | 13:41h

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

Ver diretriz: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

---

Estudo RECOVERY – 2 anos.

31 Mar, 2022 | 13:38h

The RECOVERY Trial – two years on – University of Oxford

Conteúdos relacionados:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

 

Comentário no Twitter

"One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of researchers, doctors, nurses, statisticians and supporting staff."https://t.co/cDlCUkG4cD

— Martin Landray (@MartinLandray) March 28, 2022

 

---

Relato de caso | Os danos da antibioticoprofilaxia pós-operatória.

31 Mar, 2022 | 13:36h

The Harms of Postoperative Antibiotic Prophylaxis: A Teachable Moment – JAMA Internal Medicine (gratuito por tempo limitado)

---

Bacteriemia por S. aureus complicada e não complicada: uma pesquisa internacional Delphi entre especialistas em doenças infecciosas sobre definições e tratamento.

31 Mar, 2022 | 13:34h

Complicated and uncomplicated S. aureus bacteremia: an international Delphi survey among infectious diseases experts on definitions and treatment – Clinical Microbiology and Infection

---

Estudo mostra que é comum o excesso de tratamento em pacientes com diabetes tipo 2 residentes em casas de repouso.

31 Mar, 2022 | 13:30h

Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes – Journal of the American Geriatrics Society

Comentários:

Overtreatment of T2DM Common Among VA Nursing Home Residents – HealthDay

Diabetes treatment deintensification uncommon in nursing home residents – medwire News

---

M-A | Anormalidades do parênquima pulmonar após internação por COVID-19 e pneumonite viral.

31 Mar, 2022 | 13:29h

Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis – Thorax

---

Análise sistemática para o Global Burden of Disease 2019 Study | Impacto global, regional e nacional de doenças e lesões para adultos de 70 anos de idade ou mais.

31 Mar, 2022 | 13:27h

Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study – The BMJ

 

Comentário no Twitter

See our new paper prepared within @IHME_UW! #BMJ

Life expectancy ≥70 has continued to rise globally. #Disability burden remained constant, suggesting the need to enhance public health and intervention programmes to improve wellbeing among older adults.https://t.co/TegmWQ3048

— Maciej Banach (@maciejbanach) March 14, 2022

 

---

Estudo de coorte retrospectiva | Riscos de anafilaxia com formulações intravenosas de ferro.

31 Mar, 2022 | 13:19h

Risks for Anaphylaxis With Intravenous Iron Formulations: A Retrospective Cohort Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Risk of Severe Allergic Reaction Higher with Two Intravenous Iron-Boosting Products – Rutgers University

Comentário: Risks for Anaphylaxis Compared Among IV Iron Products – HealthDay

---

Revisão sistemática | Intervenções para reduzir a inflamação na Febre Familiar do Mediterrâneo.

31 Mar, 2022 | 13:11h

Interventions for reducing inflammation in familial Mediterranean fever – Cochrane Library

Resumo: Medicines for reducing inflammation in people with familial Mediterranean fever – Cochrane Library

---